Biotech Finds Mid-Week Success After Meeting Primary Endpoint

Sponsored:

Wednesday, May 28, 2025

A biotech company based out of Massachusetts found a tremendous amount of success mid-week after the company announced that the pivotal Phase 3 PIVOT-PO trial evaluating tebipenem HBr, an investigational oral treatment for complicated urinary tract infections (cUTIs), met its primary end point and will stop early for efficacy, according to a recent press release.

Traders wasted no time snatching up shares of Spero Therapeutics Inc. (Nasdaq:SPRO), pushing the small cap to close the session up at $2.35/share (+244.57%). This move was a massive breakout from the multi-month downtrend this stock was stuck in since last year.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Sponsored: